Co-administration of Na-EDTA and diminazene aceturate (DA) to mice infected with DA-resistant Trypanosoma brucei.
This study investigated the effects of co-administration of Na-EDTA and diminazene aceturate (DA) on the level of parasitaemia (LOP), parasite clearance, packed cell volume (PCV) and post-infection survival time (PIST) in mice infected with DA-resistant Trypanosoma brucei. Five groups of 10 mice were treated as follows: infected and treated with Na-EDTA+DA; infected and treated with DA alone; infected and treated with Na-EDTA alone; infected-untreated; and uninfected-untreated. The co-administration of Na-EDTA and DA led to reduced LOP and improvements in PCV (P<0.05), as compared with treatment with DA alone. Mice treated with Na-EDTA+DA had a marginally (P>0.05) higher PIST than did mice treated with DA alone. Comparison of the group given Na-EDTA alone with the infected-untreated group showed that the former group had a significantly lower (P<0.01) LOP, improved PCV (P<0.05) and higher (P<0.01) PIST. It was concluded that the co-administration of Na-EDTA and DA led to a slight potentiation of DA in the treatment of mice infected with DA-resistant T. brucei, and that the administration of Na-EDTA alone significantly enhanced the resistance of the infected mice.
Ihedioha
J I
JI
Departments of Veterinary Pathology and Microbiology, University of Nigeria Nsukka, PO Box 3236, Nsukka 410001, Nigeria. jiiferh@yahoo.com
Ochiogu
I S
IS
Ihedioha
T E
TE
D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D000818:Animals; D002614:Chelating Agents / Q000627:therapeutic use*; D004133:Diminazene / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004351:Drug Resistance / Q000187:drug effects*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004492:Edetic Acid / Q000627:therapeutic use*; D006400:Hematocrit; D008136:Longevity / Q000187:drug effects; D008297:Male; D051379:Mice; D018512:Parasitemia / Q000188:drug therapy / Q000401:mortality; D010273:Parasitic Diseases, Animal / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D014344:Trypanocidal Agents / Q000627:therapeutic use*; D014346:Trypanosoma brucei brucei / Q000187:drug effects; D014353:Trypanosomiasis, African / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
D002614:Chelating Agents; D014344:Trypanocidal Agents; D004492:Edetic Acid; D004133:Diminazene